Minimal residual disease (MRD) screening is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN

Minimal residual disease (MRD) detection is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN

Liquid biopsy has emerged as a promising method for detecting minimal residual disease (MRD) in lymphoma. Unlike traditional tissue biopsies, which are invasive, liquid biopsy analyzes cell-free DNA present in bodily fluids such as blood. This minimally invasive procedure allows for continuous monitoring of MRD levels, delivering valuable data to g